Skip to main content

Clinical trials and vaccine introductions

  • MenAfriVac, meningococcal A conjugate vaccine: Conducted clinical trials from 2004 to 2013. Data from 8100 participants contributed to the licensure and introduction of MenAfriVac in 2010. CVD-Mali’s ongoing surveillance documented the disappearance of the disease in Mali.
  • RotaTeq®: One of three sites in sub-Saharan Africa in a multi-center, placebo-controlled Phase 3 trial. Data from the trial and GEMS supported successful application to GAVI for introduction in early 2014.
  • Trivalent inactivated influenza vaccine (TIV, Vaxigrip®): Performed a Phase IV, prospective, randomized, controlled trial to measure the efficacy, safety, and immunogenicity of TIV in pregnant women and infants. A total of 4193 pregnant women and infants were enrolled and followed for six months after delivery. Influenza vaccination in pregnancy resulted in a 68 percent reduction in influenza in infants less than four months of age.
  • Ebola Vaccine: In response to the Ebola epidemic in August 2014, CVD-Mali conducted the first human trials of ChAd3-EBO-Z in Africa. The data generated informed decisions on the vaccine dose. CVD-Mali continues to conduct Ebola vaccine trials in children and adults.

Samba Sow, MD, MS
Director General CVD-Mali and Adjunct Professor of Medicine at the University of Maryland School of Medicine

CVD-Mali Fact Sheet